期刊文献+

肺耐药相关蛋白与肿瘤多药耐药相关性的研究进展 被引量:1

Advances of the Correlation between the LRP and MDR of Tumor
在线阅读 下载PDF
导出
摘要 耐药相关蛋白(LRP)又叫主穹隆蛋白(MVP),是一种在人体内普遍表达的蛋白,构成了细胞内已知的最大蛋白质之一——穹隆体,并参与核孔复合物的组成,对细胞核质物质转运起重要作用。随着对其的深入研究,发现LRP在细胞的生理代谢、自身保护、抗凋亡、抗感染、肿瘤的恶变以及多药耐药(MDR)的形成等过程中起着重要作用,同时其表达程度与肿瘤治疗效果以及预后也有一定的相关性。 Lung resistance-related protein (LRP), also named as major vault protein (MVP) , is widely expressed in human tissue. It constructs one of the largest protein in cell which is called Vault. It is a main component of nuclear pore complex and plays an important role in nucleo-cytoplasmic transport. It is shown that LRP plays an important role in the metabolism, conservation, anti-apoptosis, anti-infection, as well as in the development of multidurg resistance and canceration of tumors. At the same time, researches show that the expression of LRP is correlated with the curative effect and prognosis of tumor.
作者 刘津 唐安洲
出处 《医学综述》 2009年第19期2944-2948,共5页 Medical Recapitulate
基金 广西科学研究与技术开发计划(桂科攻0322024-1A)
关键词 肺耐药相关蛋白 穹隆 多药耐药 肿瘤 Lung resistance-related protein Vault Multidrug resistance Tumor
  • 相关文献

参考文献2

二级参考文献20

  • 1颜笑健,梁立治,曾宗渊,刘继红,袁颂华,魏梅.铂类化疗敏感型卵巢上皮癌复发的影响因素[J].癌症,2005,24(6):751-754. 被引量:14
  • 2李文锦,颜士杰,钱和年,张香云,王建六,李小平,宋和存,贾鉴慧,林文玉.卵巢粘液性囊腺癌EGFR、neu、PCNA的表达与临床病理研究[J].浙江肿瘤,1996,2(2):67-69. 被引量:3
  • 3Brinkhuis M, Izquierdo M A, Baak J P, et al. Expression of muhidrug resistance-associated markers, their relation to quantitative athologic tumor characteristics and prognosis in advanced ovarian cancer [J]. Anal Cell Pathol, 2002,24( 1): 17-23.
  • 4Izquierdo M A, van der Zee A G, Vermorken J B, et al. Drug resistance-associated marker Lrp for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma [J]. Natl Cancer Inst, 1995,87(16) : 1230-1237.
  • 5Arts H J, Katsaros D, de Vries E G, et al. Drug resistanceassociated markers P-glycoprotein, muhidrug resistancassociated protein 1, muhidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma [ J]. Clin Cancer Res, 1999,5 (10) : 2798-2805.
  • 6Gross M E, Shazer R L, Agus D B. Targeting the HER- kinaseaxisin cancer [ J ]. Semin Oncol, 2004,31 (13) : 9-20.
  • 7Park S J, Armstrong S, Kim C H, et al. Lack of EGF receptor contributes to drug sensitivity of human germline ceils [J]. Br J Cancer, 2005,92(2) : 334-341.
  • 8Coley H M, Shotton C F, Ajose-Adeogun A, et al. Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents [J]. Biochem Pharmacol, 2006,72(8) :941-948.
  • 9Burtness B, Goldwasser M A, Flood W, et al. Phase m randomized trial of cisplatirl plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an eastern cooperative ontology group study [J]. J Clin Oncol, 2005,23 (34) : 8646-8654
  • 10Secord A A, Blessing J A, Armstrong D K, et al. Phase Ⅱ trial of cetuximab and carboplatin in relapsed platinumsensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study [J]. Gynecol Oncol, 2008,108(3) :493-499.

共引文献13

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部